Lipocine Inc. (LPCN)
$2.19-$0.06 (-2.69%) Today
Latest LPCN Insider Trades
John W. Higuchi - DirectorOpen-market purchase$81K
John W. Higuchi - DirectorJohn W. Higuchi - Director
Mahesh V. Patel - OfficerMahesh V. Patel - OfficerMahesh V. Patel - OfficerJohn W. Higuchi - DirectorLipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 5 | 60,073 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
14 Form 4 filings on record, the earliest from Dec 30, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Michael Grissinger - Director | Grant or award | Stock Option (Right to Buy) | 2,000 | $2.11 | $4K | |
| Mahesh V. Patel - Officer | Grant or award | Stock Option (Right to Buy) | 52,781 | $2.49 | $131K | |
| John W. Higuchi - Director | Grant or award | Common Stock (Right to Buy) | 1,764 | $2.19 | $4K | |
| Jill M. Jene - Director | Grant or award | Stock Option (Right to Buy) | 1,764 | $2.19 | $4K | |
| Richard Dana Ono - Director | Grant or award | Common Stock (Right to Buy) | 1,764 | $2.19 | $4K | |
| John W. Higuchi - Director | Open-market purchase | Common stock | 40,000 | $2.03 | $81K | |
| John W. Higuchi - Director | Open-market purchase | Common stock | 123,000 | $2.05 | $252K | |
| Mahesh V. Patel - Officer | Open-market purchase | Common stock | 25,000 | $2.03 | $51K | |
| Mahesh V. Patel - Officer | Open-market purchase | Common stock | 25,000 | $2.02 | $51K | |
| Mahesh V. Patel - Officer | Grant or award | Stock Option (Right to Buy) | 25,000 | $8.00 | $200K | |
| Mahesh V. Patel - Officer | Grant or award | Stock Option (Right to Buy) | 8,629 | $4.20 | $36K | |
| Krista Fogarty - Officer | Grant or award | Stock Option (Right to Buy) | 20,786 | $4.20 | $87K | |
| Mahesh V. Patel - Officer | Grant or award | Stock Option (Right to Buy) | 26,691 | $4.80 | $128K | |
| Krista Fogarty - Officer | Grant or award | Stock Option (Right to Buy) | 5,943 | $4.80 | $29K |
Lipocine Inc. (LPCN) had 5 insider filings in the last 90 days, with the most recent on 2026-08-07. The full record for LPCN runs to 14 Form 4 filings, the earliest from 2024-12-30. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of LPCN were filed in the last 90 days. 4 purchases are on record for this company.
No insider sales of LPCN were filed in the last 90 days.
This page tracks LPCN Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add LPCN to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
$LPSLLaunchpad Streetlight Acquisition Corp
$LQMTLIQUIDMETAL TECHNOLOGIES INC
$LRFCLogan Ridge Finance Corp.
$LSBALaw's Business Group Holding Ltd
$LSBKLake Shore Bancorp, Inc. /MD/
$LSTALISATA THERAPEUTICS, INC.
$LTCHLatch, Inc.
$LTGOLatigo Biotherapeutics, Inc.
$LTGRLong Table Growth Corp.
$LTRYLottery.com Inc.Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.